Literature DB >> 16517241

Determining the duration of antidepressant treatment: application of signal detection methodology and the need for duration adaptive designs (DAD).

Harold A Sackeim1, Steven P Roose, Philip W Lavori.   

Abstract

BACKGROUND: With remission now the treatment goal, antidepressant trial duration has increased. However, most patients do not remit and are exposed to prolonged, ineffective treatment.
METHODS: Conditional probabilities and signal detection methodology were contrasted in early detection of nonremitters in three comparator, 12-week antidepressant trials conducted in late- or mid-life depression.
RESULTS: The mid- and late-life samples did not differ in rates or time-to-onset of remission or accuracy of early identification of nonremission. Using conditional probabilities, there were marked differences in predictive power depending on the remission criterion. With signal detection methods, sensitivity and specificity of early identification were uniform across the differing medication conditions, remission criteria, and the three studies. By week 6, > or = 60% of ultimate nonremitters were identified, while maintaining a false positive rate < or = 20%.
CONCLUSIONS: The goals of providing maximal opportunity to achieve remission, while minimizing exposure to ineffective treatment can be satisfied by use of duration adaptive designs (DAD). While use of conditional probabilities has been the traditional method for early detection of nonremitters, this approach is inferior to use of signal detection methods. The findings also contradicted the widely held view that patients with late-life depression require longer treatment duration.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16517241     DOI: 10.1016/j.biopsych.2005.08.033

Source DB:  PubMed          Journal:  Biol Psychiatry        ISSN: 0006-3223            Impact factor:   13.382


  10 in total

1.  Does study design influence outcome?. The effects of placebo control and treatment duration in antidepressant trials.

Authors:  Bret R Rutherford; Joel R Sneed; Steven P Roose
Journal:  Psychother Psychosom       Date:  2009-03-24       Impact factor: 17.659

2.  Early Symptom Trajectories as Predictors of Treatment Outcome for Citalopram Versus Placebo.

Authors:  Sigal Zilcha-Mano; Steven P Roose; Patrick J Brown; Bret R Rutherford
Journal:  Am J Geriatr Psychiatry       Date:  2017-02-03       Impact factor: 4.105

3.  Distinct functional networks associated with improvement of affective symptoms and cognitive function during citalopram treatment in geriatric depression.

Authors:  Andreea Oliviana Diaconescu; Elisse Kramer; Carol Hermann; Yilong Ma; Vijay Dhawan; Thomas Chaly; David Eidelberg; Anthony Randal McIntosh; Gwenn S Smith
Journal:  Hum Brain Mapp       Date:  2010-09-30       Impact factor: 5.038

4.  Serotonin transporter occupancy and the functional neuroanatomic effects of citalopram in geriatric depression.

Authors:  Gwenn S Smith; Alan Kahn; Julia Sacher; Pablo Rusjan; Thilo van Eimeren; Alastair Flint; Alan A Wilson
Journal:  Am J Geriatr Psychiatry       Date:  2011-12       Impact factor: 4.105

Review 5.  Antidepressants for people with epilepsy and depression.

Authors:  Melissa J Maguire; Jennifer Weston; Jasvinder Singh; Anthony G Marson
Journal:  Cochrane Database Syst Rev       Date:  2014-12-03

6.  Treating depression to remission in older adults: a controlled evaluation of combined escitalopram with interpersonal psychotherapy versus escitalopram with depression care management.

Authors:  Charles F Reynolds; Mary Amanda Dew; Lynn M Martire; Mark D Miller; Jill M Cyranowski; Eric Lenze; Ellen M Whyte; Benoit H Mulsant; Bruce G Pollock; Jordan F Karp; Ariel Gildengers; Katalin Szanto; Alexandre Y Dombrovski; Carmen Andreescu; Meryl A Butters; Jennifer Q Morse; Patricia R Houck; Salem Bensasi; Sati Mazumdar; Jacqueline A Stack; Ellen Frank
Journal:  Int J Geriatr Psychiatry       Date:  2010-11       Impact factor: 3.485

7.  Improving the antidepressant efficacy of transcranial magnetic stimulation: maximizing the number of stimulations and treatment location in treatment-resistant depression.

Authors:  William M McDonald; Valerie Durkalski; Edward R Ball; Paul E Holtzheimer; Martina Pavlicova; Sarah H Lisanby; David Avery; Berry S Anderson; Ziad Nahas; Paul Zarkowski; Harold A Sackeim; Mark S George
Journal:  Depress Anxiety       Date:  2011-09-02       Impact factor: 6.505

Review 8.  A systematic approach to pharmacotherapy for geriatric major depression.

Authors:  Benoit H Mulsant; Daniel M Blumberger; Zahinoor Ismail; Kiran Rabheru; Mark J Rapoport
Journal:  Clin Geriatr Med       Date:  2014-06-14       Impact factor: 3.076

9.  Dynamic prediction of treatment response in late-life depression.

Authors:  Ian Joel; Amy E Begley; Benoit H Mulsant; Eric J Lenze; Sati Mazumdar; Mary Amanda Dew; Daniel Blumberger; Meryl Butters; Charles F Reynolds
Journal:  Am J Geriatr Psychiatry       Date:  2013-02-06       Impact factor: 4.105

10.  Antidepressants for people with epilepsy and depression.

Authors:  Melissa J Maguire; Anthony G Marson; Sarah J Nevitt
Journal:  Cochrane Database Syst Rev       Date:  2021-04-16
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.